Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study

Cytokine

Volumn 60, Issue 3, 2012, Pages 882-889

  Charbonneau, Bridget ^a   Maurer, Matthew J ^a   Ansell, Stephen M ^a   Slager, Susan L ^a   Fredericksen, Zachary S ^a   Ziesmer, Steven C ^a   Macon, William R ^a   Habermann, Thomas M ^a   Witzig, Thomas E ^a   Link, Brian K ^b   Cerhan, James R ^a   Novak, Anne J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Biomarkers; Case control; Cytokines; Non Hodgkin lymphoma

Indexed keywords

ALPHA INTERFERON; CXCL9 CHEMOKINE; CYTOKINE; EOTAXIN; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; GENDER; HUMAN; LARGE CELL LYMPHOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; LYMPHOCYTES; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; ODDS RATIO; YOUNG ADULT;

EID: 84867992861     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.08.028     Document Type: Article

References (45)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
2. Zelenetz A.D., Abramson J.S., Advani R.H., Andreadis C.B., Byrd J.C., Czuczman M.S., et al. NCCN clinical practice guidelines in oncology non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010, 8:288-334.
3. Morton L.M., Wang S.S., Devesa S.S., Hartge P., Weisenburger D.D., Linet M.S. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
4. Freedman A. Follicular lymphoma: 2011 update on diagnosis and management. Am J Hematol 2011, 86:768-775.
5. Fisher S.G., Fisher R.I. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004, 23:6524-6534.
6. Ekstrom Smedby K., Vajdic C.M., Falster M., Engels E.A., Martinez-Maza O., Turner J., et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008, 111:4029-4038.
7. Engels E.A. Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidem Biomar Prev 2007, 16:401-404.
8. Purdue M.P., Lan Q., Kricker A., Grulich A.E., Vajdic C.M., Turner J., et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin lymphoma study. Carcinogenesis 2007, 28:704-712.
9. Wang S.S., Cozen W., Cerhan J.R., Colt J.S., Morton L.M., Engels E.A., et al. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res 2007, 67:5042-5054.
10. Cerhan J.R., Ansell S.M., Fredericksen Z.S., Kay N.E., Liebow M., Call T.G., et al. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 2007, 110:4455-4463.
11. Forrest M.S., Skibola C.F., Lightfoot T.J., Bracci P.M., Willett E.V., Smith M.T., et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Brit J Haematol 2006, 134:180-183.
12. Nieters A., Beckmann L., Deeg E., Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006, 7:615-624.
13. Breen E.C., Boscardin W.J., Detels R., Jacobson L.P., Smith M.W., O'Brien S.J., et al. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter-592 C/C genotype. Clin Immunol 2003, 109:119-129.
14. Breen E.C., Hussain S.K., Magpantay L., Jacobson L.P., Detels R., Rabkin C.S., et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidem Biomark Prev 2011, 20:1303-1314.
15. Breen E.C., van der Meijden M., Cumberland W., Kishimoto T., Detels R., Martinez-Maza O. The development of AIDS-associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6. Clin Immunol 1999, 92:293-299.
16. Gu Y., Shore R.E., Arslan A.A., Koenig K.L., Liu M., Ibrahim S., et al. Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study. Cancer Cause Control 2010, 21:1323-1333.
17. Purdue M.P., Lan Q., Bagni R., Hocking W.G., Baris D., Reding D.J., et al. Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. Cancer Res 2011, 71:4898-4907.
18. Saberi Hosnijeh F., Krop E.J., Scoccianti C., Krogh V., Palli D., Panico S., et al. Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European prospective investigation into cancer and nutrition. Cancer Epidem Biomark Prev 2010, 19:1577-1584.
19. Rabkin C.S., Engels E.A., Landgren O., Schuurman R., Constanza Camargo M., Ruth P., et al. Circulating cytokine levels Epstein-Barr viremia and risk of acquired immunodeficiency syndrome-related non-Hodgkin lymphoma. Am J Hematol 2011, 86:875-878.
20. Ansell S.M., Maurer M.J., Ziesmer S.C., Slager S.L., Habermann T.M., Link B.K., et al. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. Am J Hematol 2012.
21. Cerhan J.R., Fredericksen Z.S., Wang A.H., Habermann T.M., Kay N.E., Macon W.R., et al. Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. Int J Mol Epidem Genet 2011, 2:95-113.
22. Drake M.T., Maurer M.J., Link B.K., Habermann T.M., Ansell S.M., Micallef I.N., et al. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol 2010, 28:4191-4198.
23. Coupland S.E. The challenge of the microenvironment in B-cell lymphomas. Histopathology 2011, 58:69-80.
24. Bien E., Balcerska A. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers 2008, 13:1-26.
25. Witkowska A.M. On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediat Inflamm 2005, 2005:121-130.
26. Whittington R., Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993, 46:446-514.
27. Jo S.A., Hwang S.H., Chang C.L., Kim S.Y., Shin H.J., Chung J.S., et al. Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Ralpha) in patients with non-Hodgkin's lymphoma. Korean J Lab Med 2010, 30:600-605.
28. Morito T., Fujihara M., Asaoku H., Tari A., Sato Y., Ichimura K., et al. Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma. Cancer Sci 2009, 100:1255-1260.
29. Yang Z.Z., Grote D.M., Ziesmer S.C., Manske M.K., Witzig T.E., Novak A.J., et al. Soluble IL-2Ralpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 2011, 118:2809-2820.
30. Seckinger P., Williamson K., Balavoine J.F., Mach B., Mazzei G., Shaw A., et al. A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J Immunol 1987, 139:1541-1545.
31. Hannum C.H., Wilcox C.J., Arend W.P., Joslin F.G., Dripps D.J., Heimdal P.L., et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990, 343:336-340.
32. Horai R., Nakajima A., Habiro K., Kotani M., Nakae S., Matsuki T., et al. TNF-alpha is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J Clin Invest 2004, 114:1603-1611.
33. Labidi S.I., Menetrier-Caux C., Chabaud S., Chassagne C., Sebban C., Gargi T., et al. Serum cytokines in follicular lymphoma correlation of TGF-beta and VEGF with survival. Ann Hematol 2009.
34. Watford W.T., Moriguchi M., Morinobu A., O'Shea J.J. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 2003, 14:361-368.
35. Younes A., Pro B., Robertson M.J., Flinn I.W., Romaguera J.E., Hagemeister F., et al. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 2004, 10:5432-5438.
36. Yang Z.Z., Grote D.M., Ziesmer S.C., Niki T., Hirashima M., Novak A.J., et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 2012, 122:1271-1282.
37. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
38. Liao F., Rabin R.L., Yannelli J.R., Koniaris L.G., Vanguri P., Farber J.M. Human Mig chemokine: biochemical and functional characterization. J Exp Med 1995, 182:1301-1314.
39. Li A., Dubey S., Varney M.L., Dave B.J., Singh R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170:3369-3376.
40. Nacinovic-Duletic A., Stifter S., Dvornik S., Skunca Z., Jonjic N. Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. Int J Lab Hematol 2008, 30:230-239.
41. Dufour J.H., Dziejman M., Liu M.T., Leung J.H., Lane T.E., Luster A.D. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002, 168:3195-3204.
42. Singh U.P., Singh S., Taub D.D., Lillard J.W. Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-/- mice. J Immunol 2003, 171:1401-1406.
43. Tannenbaum C.S., Tubbs R., Armstrong D., Finke J.H., Bukowski R.M., Hamilton T.A. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998, 161:927-932.
44. Tannenbaum C.S., Wicker N., Armstrong D., Tubbs R., Finke J., Bukowski R.M., et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 1996, 156:693-699.
45. Miedema F., Petit A.J., Terpstra F.G., Schattenkerk J.K., de Wolf F., Al B.J., et al. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest 1988, 82:1908-1914.